ID   JL-1
AC   CVCL_2080
SY   JL1
DR   EFO; EFO_0006448
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473060
DR   BioSample; SAMN10988459
DR   cancercelllines; CVCL_2080
DR   Cell_Model_Passport; SIDM01696
DR   DepMap; ACH-000645
DR   DSMZ; ACC-596
DR   DSMZCellDive; ACC-596
DR   EGA; EGAS00001000610
DR   GEO; GSM887185
DR   GEO; GSM888258
DR   LiGeA; CCLE_059
DR   PharmacoDB; JL1_708_2019
DR   Progenetix; CVCL_2080
DR   Wikidata; Q54898973
RX   PubMed=15372243;
RX   PubMed=22460905;
RX   PubMed=23840376;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=33567673;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 47 hours (PubMed=23840376); ~70-80 hours (DSMZ=ACC-596).
CC   HLA typing: A*02:05,03:01; B*49:01,55:01; C*03:04,07:01; DQA1*05:02,05:02; DQB1*06:04,06:04; DRB1*04:05,11:30 (PubMed=26589293).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.03%; Native American=0%; East Asian, North=3.05%; East Asian, South=0%; South Asian=2.74%; European, North=56.74%; European, South=37.42% (PubMed=30894373).
CC   Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
ST   Source(s): DSMZ=ACC-596; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 9
ST   D16S539: 9,12
ST   D18S51: 14,15
ST   D19S433: 15
ST   D21S11: 30
ST   D2S1338: 17,19
ST   D3S1358: 18
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   D8S1179: 15
ST   FGA: 22,23
ST   Penta D: 11,12
ST   Penta E: 11,13
ST   TH01: 8,9.3
ST   TPOX: 9,11
ST   vWA: 18
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 28
//
RX   PubMed=15372243; DOI=10.1007/s00418-004-0701-1;
RA   Philippeaux M.-M., Pache J.-C., Dahoun S., Barnet M., Robert J.-H.,
RA   Mauel J., Spiliopoulos A.;
RT   "Establishment of permanent cell lines purified from human
RT   mesothelioma: morphological aspects, new marker expression and
RT   karyotypic analysis.";
RL   Histochem. Cell Biol. 122:249-260(2004).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23840376; DOI=10.1371/journal.pone.0065903; PMCID=PMC3688685;
RA   Szulkin A., Nilsonne G., Mundt F., Wasik A.M., Souri P., Hjerpe A.,
RA   Dobra K.;
RT   "Variation in drug sensitivity of malignant mesothelioma cell lines
RT   with substantial effects of selenite and bortezomib, highlights need
RT   for individualized therapy.";
RL   PLoS ONE 8:E65903-E65903(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=33567673; DOI=10.3390/cancers13040685; PMCID=PMC7915464;
RA   Keller M., Reis K., Hjerpe A., Dobra K., Aspenstrom P.;
RT   "Cytoskeletal organization correlates to motility and invasiveness of
RT   malignant mesothelioma cells.";
RL   Cancers (Basel) 13:685.1-685.20(2021).
//